Navigation Links
Bradmer announces 2008 fourth quarter and fiscal year operational and financial results
Date:3/31/2009

TSX: BMR

TORONTO, March 31 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Corporation") announced its 2008 fourth quarter and fiscal year operational and financial results.

Operational Highlights

During the year ended December 31, 2008, the Company achieved the following steps for its multi-center Phase III trial of its lead drug Neuradiab(R), a treatment for glioblastoma multiforme (GBM), the most advanced form of brain cancer:

    -   Prepared and submitted the Company's drug manufacturing data package
        and clinical dossiers to the FDA;
    -   Initiated enrollment in the Phase III GLASS-ART clinical trial;
    -   Signed contracts with and activated an initial cohort of five U.S.
        clinical trial sites;
    -   Successfully released a second GMP drug substance batch for use in
        clinical trials and filed the related update with the FDA;
    -   Submitted new data from the previous Phase II trial indicating that
        the mean time to progression free survival was 77 weeks, which
        compares favorably with other published results in newly diagnosed
        GBM (Reardon et al.; 2008 Neuro-Oncology 10:845); and
    -   Sourced and validated commercial supplies of iodine-131 outside of
        the U.S. and Europe to prevent delays in raw material supply.

Subsequent to the financial year ended December 31, 2008, the Company commenced a strategic review of its operations, as more particularly described in press releases of the Company dated February 17, 2009 and March 5, 2009. Pursuant to the strategic review, the Company has closed its Phase III GLASS ART Trial to further patient enrollment due to unforeseen delays in site initiation and recruitment, the delayed ability to complete the 60 patient "run-in phase" in a timely manner, and the inability to raise further capital at this time.

The Company
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Bradmer implements cash conservation plan
2. Bradmer provides clinical trial update and announces evaluation of strategic alternatives
3. Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
4. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
5. Bradmer announces 2008 third quarter operational and financial results
6. Bradmer to present at Rodman & Renshaw Healthcare Conference
7. Bradmer receives FDA approval to proceed with Phase III clinical trial
8. Bradmer announces 2008 first quarter operational and financial results
9. Bradmer announces new additions to management team
10. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
11. Notice of Bradmer Pharmaceuticals Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... According to ... helpfulness of a doctor is tied directly to the success of a patient who ... a two year period, measured their weight loss over that period, and compared those ...
(Date:8/27/2015)... Montana (PRWEB) , ... August 27, 2015 , ... ... Association, the average annual cost to treat a patient with hemophilia is $175,000. ... in finding a cure and improving treatment. The RMHBDA exists to help raise ...
(Date:8/27/2015)... ... August 27, 2015 , ... According to an article published ... released new guidelines to educate doctors and patients on the best practices for type ... came in 2007, so the new version is taking into account nearly a decade ...
(Date:8/27/2015)... ... August 27, 2015 , ... Allegheny General Hospital (AGH), ... adult-only medical centers in the United States to receive international recognition for an ... Extracorporeal Life Support Organization (ELSO) , an international consortium of healthcare institutions ...
(Date:8/27/2015)... ... 27, 2015 , ... About 10 percent of mothers experienced ... Coast, killing more than 1,800 people, displacing hundreds of thousands and causing widespread ... study. , While most people don’t develop persistent depression after a major disaster ...
Breaking Medicine News(10 mins):Health News:Article on Physician Influence on Weight Loss Highlights the Importance of a Doctor Who Cares, says Dr. Feiz & Associates 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 4Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2
... Jan. 14 Speaker Nancy Pelosi spoke on the ... the State Children,s Health Insurance Program (SCHIP) Reauthorization bill, which ... 139. Below are the Speaker,s remarks: "My colleagues, this is ... expect to be a strong bipartisan vote, the House will ...
... 14 The Blue Foundation for a Healthy ... Blue Shield of Florida (BCBSF), has approved $761,000 in ... Florida organizations providing health-related services to in-need Floridians."Around 20 ... executive director of The Blue Foundation for a Healthy ...
... Demonstrates Treatment Success, and Highlights Potential Factors that Affect ... C - NUTLEY, N.J., Jan. 14 Results from ... Latino patients with the hepatitis C virus (HCV), were ... Medicine (NEJM).(1) This Roche study demonstrated that HCV ...
... too costly for some centers, experts say , , ... measure of blood flow to determine where artery-opening ... the X-ray examinations now commonly used, an international ... as "fractional flow reserve" (FFR), is designed for ...
... term and the Obama administration prepares to assume power, the ... recognize the importance of public health as the foundation for ... on the president and Congress to:, ... to health care. APHA urges the administration to ensure ...
... A special series of papers in the peer-reviewed journal ... look at future directions of research on pigment biology. Model ... genetic basis of human skin color and race. The papers, ... Mary Ann Liebert, Inc., and are available online at ...
Cached Medicine News:Health News:Pelosi: SCHIP Vote Brings Us One Step Closer to Providing Health Care for 11 Million Children 2Health News:Pelosi: SCHIP Vote Brings Us One Step Closer to Providing Health Care for 11 Million Children 3Health News:Florida's Uninsured and Underinsured to Benefit from Statewide Grants 2Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 2Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 3Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 4Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 5Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 6Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 7Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 8Health News:PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine 9Health News:Blood Flow Measurement Boosts Stent Outcomes 2Health News:Blood Flow Measurement Boosts Stent Outcomes 3Health News:APHA Releases Public Health Priorities for New Congress and Administration 2Health News:Zebrafish Journal Publishes Skin Pigmentation Studies That Shed Light on the Evolution of Race 2Health News:Zebrafish Journal Publishes Skin Pigmentation Studies That Shed Light on the Evolution of Race 3
(Date:8/27/2015)... Aug. 27, 2015   Americord Registry , a ... and placenta tissue banking company, announced today ... e-commerce website. This new website makes the expecting parent,s ... interactive shopping cart and checkout process. Logo ... blood banking websites make this service difficult to purchase ...
(Date:8/27/2015)... 2015 According to a ... titled "Global Market Study on Urinary Catheters: Intermittent ... the urinary catheters market is expected to be valued at ... is anticipated to expand at a CAGR of4.1% ... by 2021. View full report TOC at: ...
(Date:8/27/2015)... Calif. , Aug. 27, 2015  CytomX ... for the treatment of cancer, today announced that ... of the company,s Board of Directors, has been ... immuno-oncology at Eli Lilly and AstraZeneca, and also ... FDA approved checkpoint inhibitor, at Bristol-Myers Squibb and ...
Breaking Medicine Technology:Cord Blood Bank Revolutionizes Process of Online Cord Blood Banking 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Market 2011-2021 ... the commercial prospects for lyophilisation technology? ...
...  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today ... the 2011 Deutsche Bank BioFEST scheduled for Monday, December ... Eastern Time.  The session may be accessed through the ... Relations page.  An archived version of the presentation will ...
Cached Medicine Technology:Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 2Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 3Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 4Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 5Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 6Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 7Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 8Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 9Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 10Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 11Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 12Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 13Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST 2
... (P-ANCA) is for the specific detection ... myeloperoxidase as antigen. No false-positive results ... elastase in the antigen preparation. MPO ... indirect immunofluorescence; only about 10% of ...
... Inc. (DAI) Myeloperoxidase (MPO) Enzyme-Linked Immunosorbent ... and semi-quantitative determination of IgG, A, M ... assay is used to detect antibodies ... of the assay are to be used ...
... is a solid phase two-site enzyme ... direct sandwich technique in which two ... antigenic determinants on the insulin molecule. ... react with peroxidase-conjugated anti-insulin antibodies and ...
Anti-RSV IgM Assay (ELISA)....
Medicine Products: